Literature DB >> 18381073

Osteoactivin is a novel osteoclastic protein and plays a key role in osteoclast differentiation and activity.

Matilda H-C Sheng1, Jon E Wergedal, Subburaman Mohan, K-H William Lau.   

Abstract

This study presents gene expression, protein expression, and in situ immunohistochemical evidence that osteoclasts express high levels of osteoactivin (OA), which had previously been reported to be an osteoblast-specific protein in bone. OA expression in osteoclasts was up-regulated upon receptor activator of NFkappaB ligand-induced differentiation. Suppression of functional activity of OA with neutralizing antibody reduced cell size, number of nuclei, fusion, and bone resorption activity of osteoclasts. OA was co-immunoprecipitated with integrin beta3 and beta1, indicating that OA co-localizes with integrin beta3 and/or beta1 in a hetero-polymeric complex in osteoclasts. These findings indicate that OA is a novel osteoclastic protein and plays a role in osteoclast differentiation and/or activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18381073     DOI: 10.1016/j.febslet.2008.03.030

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  33 in total

1.  miRNA-based mechanism for the commitment of multipotent progenitors to a single cellular fate.

Authors:  Mati Mann; Omer Barad; Reuven Agami; Benjamin Geiger; Eran Hornstein
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-18       Impact factor: 11.205

2.  Mutation in Osteoactivin Promotes Receptor Activator of NFκB Ligand (RANKL)-mediated Osteoclast Differentiation and Survival but Inhibits Osteoclast Function.

Authors:  Samir M Abdelmagid; Gregory R Sondag; Fouad M Moussa; Joyce Y Belcher; Bing Yu; Hilary Stinnett; Kimberly Novak; Thomas Mbimba; Matthew Khol; Kurt D Hankenson; Christopher Malcuit; Fayez F Safadi
Journal:  J Biol Chem       Date:  2015-04-02       Impact factor: 5.157

3.  Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma.

Authors:  Patrick A Ott; Omid Hamid; Anna C Pavlick; Harriet Kluger; Kevin B Kim; Peter D Boasberg; Ronit Simantov; Elizabeth Crowley; Jennifer A Green; Thomas Hawthorne; Thomas A Davis; Mario Sznol; Patrick Hwu
Journal:  J Clin Oncol       Date:  2014-09-29       Impact factor: 44.544

Review 4.  Glycoprotein nonmetastatic melanoma protein B: A key mediator and an emerging therapeutic target in autoimmune diseases.

Authors:  Pei-Suen Tsou; Amr H Sawalha
Journal:  FASEB J       Date:  2020-05-23       Impact factor: 5.191

5.  Time-dependent network analysis reveals molecular targets underlying the development of diet-induced obesity and non-alcoholic steatohepatitis.

Authors:  Hea-Young Oh; Su-Kyung Shin; Hyoung-Sam Heo; Ji-Sook Ahn; Eun-Young Kwon; Jung Han Yoon Park; Yun-Young Cho; Hae-Jin Park; Mi-Kyung Lee; Eun Jung Kim; Un-Ju Jung; Robin A McGregor; Cheol-Goo Hur; Myung-Sook Choi
Journal:  Genes Nutr       Date:  2012-11-13       Impact factor: 5.523

Review 6.  Glycoprotein Non-Metastatic Melanoma Protein B (GPNMB) and Cancer: A Novel Potential Therapeutic Target.

Authors:  Manisha Taya; Stephen R Hammes
Journal:  Steroids       Date:  2017-10-31       Impact factor: 2.668

7.  Mutation in osteoactivin decreases bone formation in vivo and osteoblast differentiation in vitro.

Authors:  Samir M Abdelmagid; Joyce Y Belcher; Fouad M Moussa; Suzanne L Lababidi; Gregory R Sondag; Kimberly M Novak; Afif S Sanyurah; Nagat A Frara; Roshanak Razmpour; Fabiola E Del Carpio-Cano; Fayez F Safadi
Journal:  Am J Pathol       Date:  2014-01-23       Impact factor: 4.307

8.  Glycoprotein nonmetastatic melanoma protein b, a melanocytic cell marker, is a melanosome-specific and proteolytically released protein.

Authors:  Toshihiko Hoashi; Shinichi Sato; Yuji Yamaguchi; Thierry Passeron; Kunihiko Tamaki; Vincent J Hearing
Journal:  FASEB J       Date:  2010-01-07       Impact factor: 5.191

9.  ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angiogenic properties.

Authors:  April A N Rose; Matthew G Annis; Zhifeng Dong; Francois Pepin; Michael Hallett; Morag Park; Peter M Siegel
Journal:  PLoS One       Date:  2010-08-10       Impact factor: 3.240

10.  Role of microRNA-150 and glycoprotein nonmetastatic melanoma protein B in angiogenesis during hyperoxia-induced neonatal lung injury.

Authors:  Telugu Narasaraju; Dhananjay Shukla; Sunil More; Chaoqun Huang; Li Zhang; Xiao Xiao; Lin Liu
Journal:  Am J Respir Cell Mol Biol       Date:  2015-02       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.